Overview
News
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Total raised
$5.1M
1 round on record
Latest round
$5.1M
Venture round · May 2024 · 2 yr ago
Team
6
US Form 5500 (plan participants) · Dec 2025 · -40% in a year
Backers
1
Launchpad Venture Group
The money's age
Long since its last round
28 months since the last round · not hiring
Momentum
0/100
no fresh signals
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Funding rounds
| Round | Date | Amount | Investors | Source |
|---|---|---|---|---|
| Venture round | May 2024 | $5.1M | — | SEC Form D |
Registers and programsofficial lists and records that name the company
| Legal entity | Kano Therapeutics Inc. | SEC Form D |
Founders and leadersfrom filings, registers and the company's site
Floris EngelhardtExecutive Officer, DirectorSEC Form D
Backed byfrom the funds' portfolios and accelerator catalogs
Launchpad Venture Group News
A better DNA material for genetic medicine
By designing and manufacturing circular single-stranded DNA molecules, MIT spinout Kano Therapeutics aims to improve the delivery, safety, and effectiveness of genetic treatments.
Read more
Report
People
Floris Engelhardt
Executive Officer, Director
Ann DeWitt
Director
John Vroom
Director
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Cambridge
United States
HQ
Let's getin touch
50-200 est. staff
238 Main Street, Cambridge, MA 02142
Financials
Total raised
$5.1M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Venture - Series Unknown | 2024 | $5.1M | Details |